Differences in adherence to antihypertensive medication regimens according to psychiatric diagnosis: Results of a Korean population-based study

Psychosomatic Medicine

Volumn 72, Issue 1, 2010, Pages 80-87

  Park, Jae Hyun ^c   Kim, Ha Kyoung ^a   Park, Jong Hyock ^b   Kim, Jong Heun ^b  

^a Seoul National Hospital   (South Korea)

^b National Cancer Center   (South Korea)

^c Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Antihypertensive agents; Cumulative medication adherence; Patient compliance; Psychiatric disorder; Severe mental illness

Indexed keywords

ADULT; AGED; ALCOHOLISM; ANTIHYPERTENSIVE THERAPY; ANXIETY DISORDER; ARTICLE; BEHAVIOR DISORDER; DEMENTIA; FEMALE; HUMAN; KOREA; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MOOD DISORDER; NEUROSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; PSYCHOSIS; SOMATOFORM DISORDER; SUBSTANCE ABUSE;

ADULT; AGE DISTRIBUTION; AGED; ANTIHYPERTENSIVE AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; COMORBIDITY; CONFIDENCE INTERVALS; FEMALE; HUMANS; HYPERTENSION; MALE; MEDICATION ADHERENCE; MENTAL DISORDERS; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; ODDS RATIO; PATIENT COMPLIANCE; PREVALENCE; PSYCHIATRIC STATUS RATING SCALES; QUESTIONNAIRES; REPUBLIC OF KOREA; RESIDENCE CHARACTERISTICS; SEVERITY OF ILLNESS INDEX;

EID: 74549148957     PISSN: 00333174     EISSN: 15347796     Source Type: Journal    
DOI: 10.1097/PSY.0b013e3181c4e3e9     Document Type: Article

References (66)

1. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, Abbott R, Godwin J, Dyer A, Stamler J. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990;335:765-774
2. Lakatta EG, Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part I: Aging arteries: a "set up" for vascular disease. Circulation 2003;107:139-146 (Pubitemid 36070946)
3. Murakami Y, Hozawa A, Okamura T, Ueshima H. Relation of blood pressure and all-cause mortality in 180,000 Japanese participants: pooled analysis of 13 cohort studies. Hypertension 2008;51:1483-1491
4. DiMatteo MR, Giordani PJ, Lepper HS, Croghan TW. Patient adherence and medical treatment outcomes: a meta-analysis. Med Care 2002;40: 794-811.
5. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42: 1206-1252 (Pubitemid 37553153)
6. Nasrallah HA, Meyer JM, Goff DC, McEvoy JP, Davis SM, Stroup TS, Lieberman JA. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res 2006;86:15-22.
7. Osborn DP, Wright CA, Levy G, King MB, Deo R, Nazareth I. Relative risk of diabetes, dyslipidaemia, hypertension and the metabolic syndrome in people with severe mental illnesses: systematic review and metaanaly-sis. BMC Psychiatry 2008;8:84.
8. Dixon L, Postrado L, Delahanty J, Fischer PJ, Lehman A. The association of medical comorbidity in schizophrenia with poor physical and mental health. J Nerv Ment Dis 1999;187:496-502.
9. Miller BJ, Paschall CB 3rd, Svendsen DP. Mortality and medical comor-bidity among patients with serious mental illness. Psychiatr Serv 2006; 57:1482-1487
10. Birkenaes AB, Opjordsmoen S, Brunborg C, Engh JA, Jonsdottir H, Ringen PA, Simonsen C, Vaskinn A, Birkeland KI, Friis S, Sundet K, Andreassen OA. The level of cardiovascular risk factors in bipolar disorder equals that of schizophrenia: a comparative study. J Clin Psychiatry 2007;68:917-923
11. Goodwin RD, Davidson KW, Keyes K. Mental disorders and cardiovascular disease among adults in the United States. J Psychiatr Res 2009; 43:239-246
12. Newcomer JW. Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry 2007;68(Suppl 4):8-13.
13. Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry 2007; 68(Suppl 1):20-27
14. Harter MC, Conway KP, Merikangas KR. Associations between anxiety disorders and physical illness. Eur Arch Psychiatry Clin Neurosci 2003; 253:313-320
15. Endicott J, Spitzer RL, Fleiss JL, Cohen J. The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 1976;33:766-771
16. Slade M, Powell R, Strathdee G. Current approaches to identifying the severely mentally ill. Soc Psychiatry Psychiatr Epidemiol 1997;32: 177-184
17. Ruggeri M, Leese M, Thornicroft G, Bisoffi G, Tansella M. Definition and prevalence of severe and persistent mental illness. Br J Psychiatry 2000;177:149-155
18. Druss BG, Bradford WD, Rosenheck RA, Radford MJ, Krumholz HM. Quality of medical care and excess mortality in older patients with mental disorders. Arch Gen Psychiatry 2001;58:565-572
19. Roberts L, Roalfe A, Wilson S, Lester H. Physical health care of patients with schizophrenia in primary care: a comparative study. Fam Pract 2007;24:34-40. (Pubitemid 46454663)
20. Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002;63:892-909.
21. Gilmer TP, Dolder CR, Lacro JP, Folsom DP, Lindamer L, Garcia P, Jeste DV. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry 2004;161:692-699
22. Nose M, Barbui C, Tansella M. How often do patients with psychosis fail to adhere to treatment programmes? A systematic review. Psychol Med 2003;33:1149-1160
23. Sun SX, Liu GG, Christensen DB, Fu AZ. Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States. Curr Med Res Opin 2007;23:2305-2312
24. Thieda P, Beard S, Richter A, Kane J. An economic review of compliance with medication therapy in the treatment of schizophrenia. Psychiatr Serv 2003;54:508-516
25. Dolder CR, Lacro JP, Jeste DV. Adherence to antipsychotic and nonpsy-chiatric medications in middle-aged and older patients with psychotic disorders. Psychosom Med 2003;65:156-162
26. Dolder CR, Furtek K, Lacro JP, Jeste DV. Antihypertensive medication adherence and blood pressure control in patients with psychotic disorders compared to persons without psychiatric illness. Psychosomatics 2005; 46:135-141
27. Piette JD, Heisler M, Ganoczy D, McCarthy JF, Valenstein M. Differential medication adherence among patients with schizophrenia and co-morbid diabetes and hypertension. Psychiatr Serv 2007;58:207-212
28. Park JH, Lee SY, Kim SY, Shin Y. Disparities in antihypertensive medication adherence in persons with disabilities and without disabilities: results of a Korean population-based study. Arch Phys Med Rehabil 2008;89:1460-1467
29. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol 1997;50:105-116
30. Steiner JF, Fihn SD, Blair B, Inut TS. Appropriate reductions in compliance among well-controlled hypertensive patients. J Clin Epidemiol 1991;44:1361-1371
31. Rudd P. Clinicians and patients with hypertension: unsettled issues about compliance. Am Heart J 1995;130:572-579
32. Sackett DL, Haynes RB, Gibson ES, Hackett BC, Taylor DW, Roberts RS, Johnson AL. Randomised clinical trial of strategies for improving medication compliance in primary hypertension. Lancet 1975;1:1205-1207
33. Hansen RA, Kim MM, Song L, Tu W, Wu J, Murray MD. Comparison of methods to assess medication adherence and classify nonadherence. Ann Pharmacother 2009;43:413-422
34. Caro JJ, Salas M, Speckman JL, Raggio G, Jackson JD. Persistence with treatment for hypertension in actual practice. CMAJ 1999;160:31-37
35. Marentette MA, Gerth WC, Billings DK, Zarnke KB. Antihypertensive persistence and drug class. Can J Cardiol 2002;18:649-656
36. Monane M, Bohn RL, Gurwitz JH, Glynn RJ, Levin R, Avorn J. Compliance with antihypertensive therapy among elderly Medicaid enrollees: the roles of age, gender, and race. Am J Public Health 1996;86:1805-1808
37. Grant RW, Singer DE, Meigs JB. Medication adherence before an increase in antihypertensive therapy: a cohort study using pharmacy claims data. Clin Ther 2005;27:773-781
38. McCombs JS, Nichol MB, Newman CM, Sclar DA. The costs of interrupting antihypertensive drug therapy in a Medicaid population. Med Care 1994;32:214-226
39. Park JH, Shin Y, Lee SY, Lee SI. Antihypertensive drug medication adherence and its affecting factors in South Korea. Int J Cardiol 2008; 128:392-398
40. Division of Chronic Disease Surveillance. 2005 Health Behavior and Chronic Disease Statistics [in Korean]. Seoul: Korea Centers for Disease Control and Prevention 2006.
41. Jo I, Ahn Y, Lee J, Shin KR, Lee HK, Shin C. Prevalence, awareness, treatment, control and risk factors of hypertension in Korea: the Ansan study. J Hypertens 2001;19:1523-1532
42. Wilber JA, Barrow JG. Hypertension-a community problem. Am J Med 1972;52:653-663
43. Health care reform for Americans with severe mental illnesses: report of the National Advisory Mental Health Council. Am J Psychiatry 1993; 150:1447-1465
44. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 2000;160: 2101-2107
45. Malta M, Strathdee SA, Magnanini MM, Bastos FI. Adherence to anti-retroviral therapy for human immunodeficiency virus/acquired immune deficiency syndrome among drug users: a systematic review. Addiction 2008;103:1242-1257
46. Tucker JS, Burnam MA, Sherbourne CD, Kung FY, Gifford AL. Substance use and mental health correlates of nonadherence to antiretroviral medications in a sample of patients with human immunodeficiency virus infection. Am J Med 2003;114:573-580
47. Dixon L. Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes. Schizophr Res 1999;35(Suppl):S93-100.
48. Owen RR, Fischer EP, Booth BM, Cuffel BJ. Medication noncompliance and substance abuse among patients with schizophrenia. Psychiatr Serv 1996;47:853-858
49. Perkins DO, Gu H, Weiden PJ, McEvoy JP, Hamer RM, Lieberman JA. Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreni-form disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. J Clin Psychiatry 2008;69:106-113
50. Wilk J, Marcus SC, West J, Countis L, Hall R, Regier DA, Olfson M. Substance abuse and the management of medication nonadherence in schizophrenia. J Nerv Ment Dis 2006;194:454-457
51. Zilberman ML, Tavares H, Blume SB, el-Guebaly N. Substance use disorders: sex differences and psychiatric comorbidities. Can J Psychiatry 2003;48:5-13.
52. Kushel MB, Vittinghoff E, Haas JS. Factors associated with the health care utilization of homeless persons. JAMA 2001;285:200-206
53. Ammassari A, Trotta MP, Murri R, Castelli F, Narciso P, Noto P, Vecchiet J, D'Arminio Monforte A, Wu AW, Antinori A. Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature. J Acquir Immune Defic Syndr 2002;31(Suppl 3): S123-7.
54. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487-497
55. Stilley CS, Sereika S, Muldoon MF, Ryan CM, Dunbar-Jacob J. Psychological and cognitive function: predictors of adherence with cholesterol lowering treatment. Ann Behav Med 2004;27:117-124
56. van Servellen G, Chang B, Garcia L, Lombardi E. Individual and system level factors associated with treatment nonadherence in human immunodeficiency virus-infected men and women. AIDS Patient Care STDS 2002;16:269-281
57. Wang PS, Bohn RL, Knight E, Glynn RJ, Mogun H, Avorn J. Noncom-pliance with antihypertensive medications: the impact of depressive symptoms and psychosocial factors. J Gen Intern Med 2002;17:504-511
58. Okuno J, Yanagi H, Tomura S. Is cognitive impairment a risk factor for poor compliance among Japanese elderly in the community? Eur J Clin Pharmacol 2001;57:589-594
59. Braithwaite RS, McGinnis KA, Conigliaro J, Maisto SA, Crystal S, Day N, Cook RL, Gordon A, Bridges MW, Seiler JF, Justice AC. A temporal and dose-response association between alcohol consumption and medication adherence among veterans in care. Alcohol Clin Exp Res 2005; 29:1190-1197
60. Bryson CL, Au DH, Sun H, Williams EC, Kivlahan DR, Bradley KA. Alcohol screening scores and medication nonadherence. Ann Intern Med 2008;149:795-803.
61. Johnson KH, Bazargan M, Bing EG. Alcohol consumption and compliance among inner-city minority patients with type 2 diabetes mellitus. Arch Fam Med 2000;9:964-970
62. Druss BG, Bradford DW, Rosenheck RA, Radford MJ, Krumholz HM. Mental disorders and use of cardiovascular procedures after myocardial infarction. JAMA 2000;283:506-511
63. Redelmeier DA, Tan SH, Booth GL. The treatment of unrelated disorders in patients with chronic medical diseases. N Engl J Med 1998;338: 1516-1520
64. Byun YC, Yoon SY, Choi MY, Suh DW, Chung HY, Cho SC, Yoon YH, Kim YW, Lee BS. A Study on the Extension Plan for Disability Categories of the Third-Stage [in Korean]. Seoul: Korea Institute for Health and Social Affairs; 2006.
65. Eraker SA, Kirscht JP, Becker MH. Understanding and improving patient compliance. Ann Intern Med 1984;100:258-268
66. Kreyenbuhl J, Dixon LB, McCarthy JF, Soliman S, Ignacio RV, Valen-stein M. Does adherence to medications for type 2 diabetes differ between individuals with vs without schizophrenia? Schizophr Bull 2008 Aug 20. [Epub ahead of print.]